DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

August 03, 2011 08:50 ET

DiaMedica Expands Scientific Advisory Board With the Appointment of John M. Amatruda, M.D.

WINNIPEG, MANITOBA--(Marketwire - Aug. 3, 2011) - DiaMedica Inc., (TSX VENTURE:DMA), a biotechnology company focused on diabetes, announced today that John M. Amatruda, M.D. has joined the company's Scientific Advisory Board ("SAB"), enhancing DiaMedica's experienced advisory team.

Dr. Amatruda was the former Senior Vice President and Franchise Head for Diabetes and Obesity at Merck Research Laboratories where he lead the development and regulatory approvals of Januvia™ and Janumet™ – the first compounds in the DPP-IV inhibitor class for Type 2 diabetes. Prior to Dr. Amatruda's tenure at Merck, he served as Vice President and Therapeutic Area Research Head for the Metabolic Disorders Research at Bayer AG, as well as a Professor of Medicine at the University of Rochester School of Medicine and an Adjunct Professor of Medicine at Yale University School of Medicine. He is board certified in internal medicine, endocrinology and metabolism. Dr. Amatruda is an author on over 150 scientific papers, abstracts, reviews and book chapters.

"We are extremely pleased to be adding a world leader in diabetes drug development to our SAB," stated Mr. Rick Pauls, President and CEO, DiaMedica Inc. "Dr. Amatruda's opinion is highly respected within the pharmaceutical industry."

"It is a pleasure to join the SAB of DiaMedica," commented Dr. Amatruda. "DiaMedica has several approaches for the treatment of diabetes and I am excited to work with the company and its scientific advisors."

About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic compounds aimed to improve the lives of patients with diabetes and other major, medically unmet diseases. DiaMedica's lead compound, DM-199, represents a novel approach to treating Type 1 and Type 2 diabetes by demonstrating significant results against three major aspects of these diseases: 1) halting the autoimmune attack on beta cells; 2) proliferating insulin producing beta cells and 3) improving glucose control.

DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the enzyme glycogen synthase kinase 3 beta (GSK3B). In preclinical studies, DM-204 significantly improved glucose control and decreased blood pressure.

The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.

Contact Information